Literature DB >> 20935469

Pre-pandemic and pandemic influenza vaccines.

Steven Rockman1, Lorena Brown.   

Abstract

Vaccination is considered the most effective strategy to control influenza and becomes particularly important when a new subtype or distantly related strain of virus enters the human population causing a world-wide epidemic or "pandemic". Depending upon the virulence of the emerging virus, a lack of pre-existing immunity can lead to overwhelming morbidity and deaths ranging in the millions. While the correlates of immunity to influenza are yet to be fully understood, our experience with vaccines over many decades enables pre-pandemic planning to develop strategies to minimise the impact of a human pandemic. This review explores developing pandemic and pre-pandemic vaccines in the context of highly virulent avian H5N1 virus and the influenza H1N1 pandemic of 2009.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20935469     DOI: 10.4161/hv.6.10.12915

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  10 in total

1.  Evaluation of multivalent H2 influenza pandemic vaccines in mice.

Authors:  Brian J Lenny; Stephanie Sonnberg; Angela F Danner; Kimberly Friedman; Richard J Webby; Robert G Webster; Jeremy C Jones
Journal:  Vaccine       Date:  2017-02-08       Impact factor: 3.641

2.  Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects.

Authors:  Iván Bihari; Gyula Pánczél; Jozsef Kovacs; Jenny Beygo; Elena Fragapane
Journal:  Clin Vaccine Immunol       Date:  2012-10-17

3.  An Intranasal Virus-Like Particle Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A Virus.

Authors:  Louis M Schwartzman; Andrea L Cathcart; Lindsey M Pujanauski; Li Qi; John C Kash; Jeffery K Taubenberger
Journal:  MBio       Date:  2015-07-21       Impact factor: 7.867

4.  Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge.

Authors:  Alex J Mann; Nicolas Noulin; Andrew Catchpole; Koert J Stittelaar; Leon de Waal; Edwin J B Veldhuis Kroeze; Michael Hinchcliffe; Alan Smith; Emanuele Montomoli; Simona Piccirella; Albert D M E Osterhaus; Alastair Knight; John S Oxford; Giulia Lapini; Rebecca Cox; Rob Lambkin-Williams
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

5.  Highly Pathogenic Avian Influenza H5 Hemagglutinin Fused with the A Subunit of Type IIb Escherichia coli Heat Labile Enterotoxin Elicited Protective Immunity and Neutralization by Intranasal Immunization in Mouse and Chicken Models.

Authors:  Neos Tang; Shi-Wei Lin; Ting-Hsuan Chen; Jia-Tsrong Jan; Hung-Yi Wu; Suh-Chin Wu
Journal:  Vaccines (Basel)       Date:  2019-11-22

Review 6.  Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines.

Authors:  Jianfeng Zhang
Journal:  Viruses       Date:  2012-11-01       Impact factor: 5.048

Review 7.  Evasion of influenza A viruses from innate and adaptive immune responses.

Authors:  Carolien E van de Sandt; Joost H C M Kreijtz; Guus F Rimmelzwaan
Journal:  Viruses       Date:  2012-09-03       Impact factor: 5.048

Review 8.  Back to the Future: Lessons Learned From the 1918 Influenza Pandemic.

Authors:  Kirsty R Short; Katherine Kedzierska; Carolien E van de Sandt
Journal:  Front Cell Infect Microbiol       Date:  2018-10-08       Impact factor: 5.293

Review 9.  Harnessing the Power of T Cells: The Promising Hope for a Universal Influenza Vaccine.

Authors:  E Bridie Clemens; Carolien van de Sandt; Sook San Wong; Linda M Wakim; Sophie A Valkenburg
Journal:  Vaccines (Basel)       Date:  2018-03-26

Review 10.  An overview of the highly pathogenic H5N1 influenza virus.

Authors:  Jingchuan Yin; Shi Liu; Ying Zhu
Journal:  Virol Sin       Date:  2013-01-16       Impact factor: 4.327

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.